ramipril vs altace
Click on image below to visit altace Online Page
BRISTOL, Tenn. — The following was released on Saturday, May 19 and is being repeated.
King Pharmaceuticals, Inc. (NYSE:KG) reported today that data from its Phase III clinical trial evaluating ALTACE([R]) (ramipril) 20mg and the combination of ALTACE 20mg and hydrochlorothiazide (HCT) 25mg were presented this weekend at the American Society of Hypertension, Inc. (ASH) Twenty-Second Annual Scientific Meeting and Exposition (ASH 2007) in Chicago, Illinois. The clinical trial data showed that ALTACE 20mg resulted in significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP). ALTACE 20mg used in combination with HCT 25mg once daily as measured by a semi-automatic digital blood pressure device (office measurements) resulted in a statistically significant greater reduction of both seated DBP and seated SBP compared to monotherapy with HCT 25mg once daily or ALTACE 20mg once daily in patients with Stage 2 Essential Hypertension defined as blood pressure equal to or greater than 160 mmHg SBP or 100 mmHg DBP.
Data from the trial also showed that ALTACE 20mg monotherapy once daily provide significant reductions in mean 24-hour SBP and DBP of 11.4 mmHg and 6.2 mmHg, respectively. Importantly, as compared to office measurements, statistically significant greater reductions in mean 24-hour blood pressure, as measured by ambulatory blood pressure monitoring, were obtained with the combination therapy. Ambulatory blood pressure measurements have been shown to correlate better than office measurements for predicting adverse effects on end organs such as the kidney, heart, or brain. The safety profile of the combination was consistent with current labeling for the individual monotherapy drugs as approved by the U.S. Food and Drug Administration (FDA).
Advertisement
Altace prescription
Altace sideeffects
Altace weight gain
Altace generic drug
Altace indications
Affects of altace
altace forum